US Bancorp DE Sells 651 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

US Bancorp DE cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 30.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,465 shares of the company’s stock after selling 651 shares during the period. US Bancorp DE’s holdings in Kymera Therapeutics were worth $69,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Swiss National Bank increased its position in Kymera Therapeutics by 12.3% in the 1st quarter. Swiss National Bank now owns 79,700 shares of the company’s stock worth $3,204,000 after buying an additional 8,700 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Kymera Therapeutics by 5.4% in the first quarter. Russell Investments Group Ltd. now owns 51,757 shares of the company’s stock worth $2,081,000 after acquiring an additional 2,646 shares during the last quarter. ProShare Advisors LLC increased its position in Kymera Therapeutics by 18.0% during the first quarter. ProShare Advisors LLC now owns 11,609 shares of the company’s stock worth $467,000 after acquiring an additional 1,775 shares during the period. State Board of Administration of Florida Retirement System increased its position in Kymera Therapeutics by 15.7% during the first quarter. State Board of Administration of Florida Retirement System now owns 12,645 shares of the company’s stock worth $508,000 after acquiring an additional 1,720 shares during the period. Finally, Vanguard Group Inc. raised its stake in Kymera Therapeutics by 19.2% during the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock valued at $191,635,000 after purchasing an additional 769,486 shares during the last quarter.

Kymera Therapeutics Stock Down 8.7 %

NASDAQ:KYMR opened at $41.96 on Monday. The firm has a market cap of $2.72 billion, a PE ratio of -17.93 and a beta of 2.21. Kymera Therapeutics, Inc. has a 12 month low of $16.94 and a 12 month high of $53.27. The company’s 50-day moving average price is $47.17 and its two-hundred day moving average price is $41.72.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. During the same quarter in the previous year, the company posted ($0.90) earnings per share. Kymera Therapeutics’s quarterly revenue was down 20.9% compared to the same quarter last year. On average, research analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analysts Set New Price Targets

KYMR has been the topic of several research reports. Leerink Partnrs upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Leerink Partners reaffirmed an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a report on Monday, September 9th. Wolfe Research upgraded Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective for the company in a research report on Monday, August 26th. Oppenheimer boosted their price objective on Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, September 27th. Finally, UBS Group reduced their target price on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Kymera Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $51.21.

Insiders Place Their Bets

In related news, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The disclosure for this sale can be found here. Insiders own 15.82% of the company’s stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.